The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Ledipasvir-sofosbuvir in Adolescents with Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy
J Pediatr Gastroenterol Nutr. 2022 Feb 10. doi: 10.1097/MPG.0000000000003406.Online ahead of print.
1Ain Shams University, Pediatric Department, Hematology/Oncology Division, Cairo, Egypt Faculty of Medicine Ain Shams University Research Institute - Clinical Research Center (MASRI-CRC) National Cancer Institute, Virology Department, Cairo, Egypt Gilead Sciences, Foster City, United States National Cancer Institute, Pediatric Oncology Department, Cairo, Egypt.
Abstract
Objectives: In children with hematological malignancies, chronic HCV infection has been associated with more rapid liver disease progression and higher risk of malignancy relapse due to chemotherapy interruption. We evaluated the safety and efficacy of ledipasvir-sofosbuvir for 12 weeks in these patients.
Methods: In a phase 2, open-label study, at one site in Egypt, patients aged 12-<18 years with chronic HCV genotype 1 or 4 infection undergoing maintenance chemotherapy for hematological malignancies received ledipasvir-sofosbuvir (90 mg/400 mg) once daily for 12 weeks. The efficacy endpoint was sustained virologic response 12 weeks after treatment (SVR12). Safety was assessed by the incidence of adverse events and clinical and laboratory data, including HCV flares defined as ALT ≥3-fold increase from Day 1 and HCV RNA elevation ≥1 × log10 from Day 1.
Results: Of the 19 adolescents enrolled and treated, median age was 14 years (range 12-17), 84% (16/19) were male, and all had HCV genotype 4 and were HCV treatment naive. All patients completed treatment and achieved SVR12 (19/19, 100%, 95% CI, 82-100). Common adverse events were pyrexia (5/19, 26%), diarrhea (4/19, 21%), and headache (4/19, 21%). Three patients experienced serious adverse events of pneumonia (2 patients), and osteoarthritis and diarrhea (1 patient); none were considered related to study drug. No patient experienced HCV flares.
Conclusions: Ledipasvir-sofosbuvir was well-tolerated and efficacious in adolescents with chronic HCV genotype 4 and leukemia undergoing maintenance chemotherapy. These data support the use of this interferon-and ribavirin-free regimen in adolescents with hematological malignancies.